TScan Therapeutics, Inc. - 8-K Filing
TScan Therapeutics announces workforce reduction of ~75%, pauses Phase 3 study, faces Nasdaq delisting risk due to bid price failure (Items: 2.05 Costs Associated with Exit or Disposal Activities, 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure)
Tickers: $TCRX